# Paget's bone disease in a nonendemic region: Exploring novel therapeutic strategies

## TL;DR

A 57-year-old woman with Paget's disease of bone was successfully treated with alendronate after experiencing side effects from another treatment.

## Contribution

The paper presents a case study of an alternative treatment approach for PDB in a nonendemic region.

## Key findings

- The patient showed elevated alkaline phosphatase levels, indicative of PDB.
- Alendronate treatment led to a reduction in alkaline phosphatase levels.
- The patient preferred oral alendronate due to side effects from intravenous zoledronic acid.

## Abstract

Paget's disease of bone (PDB) is a chronic condition causing abnormal bone remodeling, leading to pain, fractures, and complications. A 57‐year‐old female patient, asymptomatic and devoid of pain, incidentally exhibited elevated levels of alkaline phosphatase. Following a thorough consideration of potential differential diagnoses, the eventual diagnosis established was PDB. We recommended Fosamax (70 mg alendronate tablets) at two tablets twice weekly for 3 months to manage PDB due to patient preference and side effects with intravenous zoledronic acid. Subsequent assessments of alkaline phosphatase levels during follow‐up examinations post‐treatment revealed a reduction in their values.